SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go?
PFE 25.22+0.1%Dec 22 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Anthony Wong who wrote (5435)9/9/1998 2:57:00 PM
From: BI*RI  Read Replies (1) of 9523
 
Anthony,

Regarding Inhale/Pfizer.

I e-mailed the news on this new product to a friend (who I've talked into investing in PFE)who works for J&J's Lifescan division and specializes in diabetes tests and pharma treatment. His reply: "That's real good news and the data are actually very good. A reduction of over 2 % for a HbA1c reading is excellent and very significant. I'll probably buy more PFE...."

...Both groups started at unacceptable glucose levels. Of the 56 patients with complete data, the group adding inhaled insulin started at 9.8% while the group on oral agents alone started at 9.9%. Those on the oral agent alone had little change in the HbA1c level after 12 weeks and ended the 12th week at 9.8%. Those receiving pulmonary add-on therapy showed a significant improvement by reducing the HbA1c level by 2.3% to a level of 7.5%. In the group using the add-on inhaled insulin, there was only one episode of severe hypoglycemia for the entire study population requiring the assistance of another person; and an average of approximately 0.5 mild to moderate episodes per month per patient, which is consistent with improved........
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext